Home » FDA Warns Compounding Pharmacy Trio With cGMP Violations
FDA Warns Compounding Pharmacy Trio With cGMP Violations
The FDA cited a trio of compounders for a wide swath of quality violations, igniting renewed criticism that the agency is “unjustified” in using a new law to enforce old violations.
Drug Industry Daily
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct